Wonder Sciences launched Wondermed, an at‑home ketamine‑assisted treatment that pairs low‑dose, self‑administered ketamine lozenges with a structured telehealth protocol integrating psychiatry and psychology. Patients complete an eligibility survey and clinician telehealth visit, then follow a personalized weekly session plan supported by remote check‑ins, soundscapes, journaling prompts and integration resources. Wondermed charges an introductory rate of $249 per month, which includes four lozenges for self‑led sessions, clinician support, and a personalized dashboard. The company reports that 92 percent of patients experience a decrease in anxiety following their first session. Wonder Sciences is accepting patients in California, New York, Florida and Texas, plans near‑term expansion into Illinois, Arizona and Connecticut, and aims to be available in 19 states by year‑end. The company is also developing a database of partner mental health professionals to provide recommendations to patients.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2022